1
Kevin Rodzinak
Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Armstrong Donna J, Hu Essa H, Kelly Michael J Iii, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Rossi Michael A, Sanderson Philip E, Wang Jiabing, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, December 21, 2006: WO/2006/135627 (19 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J, February 16, 2012: WO/2012/021382 (19 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


3
Kevin Rodzinak
Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R: Inhibitors of akt activity. Merck & Co, Arruda Jeannie M, Campbell Brian T, Cosford Nicholas D P, Hoffman Jacob M, Hu Essa H, Layton Mark E, Li Yiwei, Liang Jun, Rodzinak Kevin J, Siu Tony, Stearns Brian A, Tehrani Lida R, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, June 22, 2006: WO/2006/065601 (17 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


4
Kevin Rodzinak
Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Naya Akira, Ogino Yoshio, Onozaki Yu, Rodzinak Kevin J, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Banyu Pharmaceutical, Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Naya Akira, Ogino Yoshio, Onozaki Yu, Rodzinak Kevin J, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing, Leff Matthew A, December 10, 2009: WO/2009/148916 (10 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


5
Kevin Rodzinak
Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E: N-alkyl-azacycloalkyl nmda/nr2b antagonists. Merck & Co, Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, October 26, 2006: WO/2006/113471 (3 worldwide citation)

Compounds represented by Formula (I): and/or pharmaceutically acceptable salts, individual enantiomers and stereoisomers thereof, are effective as NMDA/NR2B antagonists useful for treating conditions such as pain, Parkinson’s disease, Alzheimer’s disease, epilepsy, depression, anxiety, ischemic brai ...


6
Kevin Rodzinak
Layton Mark E, Rodzinak Kevin J, Sanderson Philip E: Inhibitors of akt activity. Merck & Co, Layton Mark E, Rodzinak Kevin J, Sanderson Philip E, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, June 12, 2008: WO/2008/070134 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


7
Kevin Rodzinak
Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E: 1,3-disubstituted heteroaryl nmda/nr2b antagonists. Merck & Co, Layton Mark E, Rodzinak Kevin J, Kelly Michael J Iii, Sanderson Philip E, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, February 16, 2006: WO/2006/017409 (2 worldwide citation)

Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson’s disease, Alzheimer’s disease, ...


8
ARRINGTON Kenneth L, DUDKIN Vadim, LAYTON Mark E, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, ARRINGTON Kenneth L, DUDKIN Vadim, LAYTON Mark E, PERO Joseph E, REIF Alexander J, December 15, 2011: WO/2011/156245 (17 worldwide citation)

The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseas ...


9
LAYTON Mark E, KELLY Michael J: 1,3-benzothiazol-2(3h)-ones et [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones substituées formant des effecteurs allostériques positifs de mglur2, Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2. Merck Sharp & Dohme, LAYTON Mark E, KELLY Michael J, November 3, 2011: WO/2011/137046 (17 worldwide citation)

The present invention is directed to benzothiazol-one and thiazolo pyridine-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glut ...


10
Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Ogino Yoshio, Onozaki Yu, Rossi Michael A, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing: Inhibitors of akt activity. Merck & Co, Banyu Pharmaceutical, Furuyama Hidetomo, Goto Yasuhiro, Kawanishi Nobuhiko, Layton Mark E, Mita Takashi, Ogino Yoshio, Onozaki Yu, Rossi Michael A, Sakamoto Toshihiro, Sanderson Philip E, Wang Jiabing, Merck & Co, December 10, 2009: WO/2009/148887 (8 worldwide citation)

The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibi ...



Click the thumbnails below to visualize the patent trend.